Kybella®

First & only FDA-approved injectable that contours and improves the appearance of submental fullness

 

ABOUT KYBELLA®

KYBELLA® is the first and only FDA-approved injectable drug that contours and improves the appearance of submental fullness. 

Dr. Rachel was among the first physicians in Pasadena to be trained to inject Kybella, in late 2015. Since then, she has treated dozens of satisfied clients who are amazed with their results. 

The number of injections and the number of treatments should be tailored to the individual patient’s submental fat distribution and treatment goals. Once the aesthetic response is achieved with KYBELLA®, retreatment is not expected.

 

What is submental fullness?

Submental fullness, sometimes referred to as “double chin,” is a common, yet under-treated facial aesthetic condition. It can detract from an otherwise balanced and harmonious facial appearance leading to an older and heavier look.

Submental fullness can impact a broad range of adults, including both women and men, and can be caused by aging, genetics and weight gain.

According to a 2015 survey by the American Society for Dermatologic Surgery (ASDS), over 2/3 of consumers are bothered by submental fullness – nearly as many as those bothered by lines and wrinkles around the eyes.

 

What is KYBELLA® (deoxycholic acid) injection?

KYBELLA® (deoxycholic acid) injection is the first and only FDA-approved injectable drug that contours and improves the appearance of submental fullness due to submental fat.

KYBELLA® is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

 

How does KYBELLA® work?

KYBELLA® is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. 

When injected into subcutaneous fat, KYBELLA® causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After the aesthetic response is achieved, retreatment with KYBELLA® is not expected.

 

What are the side effects with KYBELLA®?

The safety profile of KYBELLA® is well-characterized.

KYBELLA® has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which over 1,600 have been treated with KYBELLA®.

The most common adverse reactions were edema/swelling, hematoma/bruising, pain, numbness, erythema and induration.

KYBELLA® is manufactured through a highly-controlled, FDA-regulated process and approved facility to ensure patient safety.
 

< Return To Blog

Kybella® Clinical Results

  • Kybella Before & After
    Before
    After

    Actual Contempo Aesthetics patient status 7-weeks post first Kybella® treatment with 3 syringes of Kybella®. Performed by Dr. Rachel Reyes-Bergano. 

  • Kybella Before & After
    Before
    After

    Actual Contempo Aesthetics patient status 3-weeks post first Kybella® treatment with 3 syringes of Kybella®. Performed by Dr. Rachel Reyes-Bergano. 

  • Kybella®
    Before
    After

    Actual Contempo Aesthetics patient status 3-weeks post first Kybella® treatment with 2 syringes of Kybella®. Performed by Dr. Rachel Reyes-Bergano. 

  • Kybella®
    Before
    After

    Actual Contempo Aesthetics patient status 3-weeks post first Kybella® treatment with 2 syringes of Kybella®. Performed by Dr. Rachel Reyes-Bergano.